ANZCTR - Registration

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12617000335392

Ethics application status

Approved

Date submitted

27/02/2017

Date registered

3/03/2017

Date last updated

2/07/2021

Date data sharing statement initially provided

2/07/2021

Date results provided

2/07/2021

Type of registration

Retrospectively registered

Titles & IDs

Public title

A randomised stepped wedge control interventional trial assessing the impact of a novel disease management software module on disease risk factor detection, disease diagnosis rates and disease key management items in the primary care setting.

Scientific title

A randomised stepped wedge control interventional trial assessing the impact of the disease management software module (Chronic Disease IMPACT) on disease risk factor detection, disease diagnosis rates and disease key management items in the primary care setting.

Secondary ID [1]

Nil known

Universal Trial Number (UTN)

U1111-1193-5419

Trial acronym

Chronic Disease IMPACT (Chronic Disease early detection and Improved Management in PrimAry Care ProjecT)

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Chronic Kidney Disease

Type II Diabetes Mellitus

Cardiovascular Disease including Peripheral Arterial Disease, Coronary Heart Disease & Ischaemic Stroke

Heart Failure

Familial Hypercholesterolaemia

Condition category

Condition code

Cardiovascular

Coronary heart disease

Stroke

Ischaemic

Metabolic and Endocrine

Diabetes

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

The Chronic Disease IMPACT e-technology module is designed to be a one stop shop for chronic vascular disease risk factor detection, disease detection and disease management in the primary care setting. Its design is guided by a team of disease specialists, general practitioners, population health experts and the latest national disease prevention and management guidelines. The module is an add on feature to the widely used primary care clinical auditing desktop software tool, Pen CS CAT. Participating primary care practices are current users of Pen CS CAT. The module will be installed into the participating primary care practices by download of a web link. Access to the module by participating practices will be via stepped wedge entry of 2-3 practices every 16 weeks commencing April 2017 until all practices are entered. The module is to be used for the primary care routine clinical auditing activities including determination of disease detection rates & disease risk factor detection rates and proportion of patients at target/not at target for key disease management items. It will be used by general practice managers and nurses and general practitioners Education on use of the module and disease detection and management will be provided to these primary care practice staff on site or via teleconference for up to 6hrs over the 15 months (method, frequency and duration is selected by the primary care practice staff). Primary care practice staff participating in the education will be asked to complete feedback (via completion of a word document) on the education immediately after each session (approx 10 mins). Data extracts will be collected from each practice at baseline and thereon every 16 weeks for 64 weeks and collated into aggregated form for benchmark reporting back to practices. A nominated practice staff member will be asked to complete an evaluation (10 min approx. duration) of the module on a quarterly basis by email, phone or face to face (method is selected by the nominated practice staff member), Intervention adherence will be assessed via a completion of clinical auditing activity log by the nominated practice staff member on a weekly basis (up to 5 mins duration) which will record how much time was spent clinical auditing using the module, who performed the clinical auditing and what specific clinical auditing activity was carried out. This log will be completed by email, phone or face to face (method is selected by the nominated practice staff member)

Intervention code [1]

Early detection / Screening

Intervention code [2]

Prevention

Comparator / control treatment

This is a stepped wedge design. The design involves random and sequential crossover of clusters from control to intervention until all clusters are exposed to the intervention. Standard care is administered throughout the control period prior to administration of intervention

Control group

Active

Outcomes

Primary outcome [1]

Disease Detection Rates (for CVDs (Cardiovascular diseases), CHF (Congestive Heart Failure), CKD (Chronic Kidney Disease), T2DM (type 2 Diabetes Mellitus) and FH (Familial Hypercholesterolaemia)) will be assessed by extraction of deindentified clinical audting data (specifically the clinically recorded diagnosis for each disease) collected via the Pen CS CAT tool from the participating primary care practices

Timepoint [1]

15 months post baseline extraction

Primary outcome [2]

Disease Risk Factor Detection Rates (for CVDs, CHF CKD, T2DM and FH) will be assessed by extraction of deindentified clinical auditing data (specifically risk factors for each disease) collected via the Pen CS CAT tool from the participating primary care practices. Risk factors are those defined by national guidelines including
(1) RACGP Redbook (9th edition)
(2) National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing
Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia. Updated October 2011.
(3) Chronic Kidney Disease (CKD) Management in General Practice (3rd edition).
Kidney Health Australia, Melbourne, 2015.
(4) The Royal Australian College of General Practitioners. General practice management of type 2 diabetes: 2016–18. East Melbourne, Vic: RACGP (2016)
(5) National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012,

Timepoint [2]

15 months post baseline Extraction

Primary outcome [3]

Disease Key Management Items (for CVDs, CHF, CKD, T2DM and FH) will be assessed by extraction of deindentified clinical audting data collected via the Pen CS CAT tool from the participating primary care practices. Disease management items are those defined by national guidelines including
(1) The Royal Australian College of General Practitioners. General practice management of type 2 diabetes: 2016–18. East Melbourne, Vic: RACGP (2016)
(2) National Stroke Foundation. Clinical Guidelines for stroke Management (2010),
(3) National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing
Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia. Updated October 2011.
(4) Chronic Kidney Disease (CKD) Management in General Practice (3rd edition).
Kidney Health Australia, Melbourne, 2015.
(5) National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults (2016)
(6) National Heart Foundation of Australia and the Cardiac Society of Australia and New
Zealand. Reducing risk in heart disease: an expert guide to clinical practice for secondary prevention of
coronary heart disease. Melbourne: National Heart Foundation of Australia (2012)

Timepoint [3]

15 months post baseline extraction

Secondary outcome [1]

Quantification of Medicare Benefits Schedule (MBS) items costs will be assessed by data linkage between deidentified MBS items and deidentified primary care practice data

Timepoint [1]

up to 10 years post baseline extraction

Secondary outcome [2]

Quantification of Pharmaceutical Benefits Scheme (PBS) items costs will be assessed by data linkage between deidentified PBS items and deidentified primary care practice data

Timepoint [2]

up to 10 years post baseline extraction

Secondary outcome [3]

Time to death for patients managed during the intervention phase of the Primary care practice will be measured by data linkage between death registry deidentified data and deidentified primary care data

Timepoint [3]

Up to 10 years post baseline extraction

Secondary outcome [4]

Rates of hospitalisation will be measured by data linkage between deidentified hospital data and deidentified primary care data

Timepoint [4]

Upto 10 years post baseline extraction

Eligibility

Key inclusion criteria

Any active primary care practice (general practice) in the State of Victoria, Australia

Minimum age

18 Years

Maximum age

No limit

Sex

Both males and females

Can healthy volunteers participate?

Yes

Key exclusion criteria

none

Study design

Purpose of the study

Prevention

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Concealed allocation was performed by use of sealed opaque envelopes

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Masking / blinding

Open (masking not used)

Who is / are masked / blinded?

Intervention assignment

Crossover

Other design features

Practices will be stepped into receiving the intervention quarterly over 15 months

Phase

Not Applicable

Type of endpoint/s

Efficacy

Statistical methods / analysis

Sample size is the number of primary care practice sites

Recruitment

Recruitment status

Completed

Date of first participant enrolment

Anticipated

Actual

14/11/2016

Date of last participant enrolment

Anticipated

30/03/2018

Actual

30/03/2018

Date of last data collection

Anticipated

1/08/2026

Actual

11/07/2019

Sample size

Target

Accrual to date

Final

Recruitment in Australia

Recruitment state(s)

VIC

Funding & Sponsors

Funding source category [1]

Other

Name [1]

North Western Melbourne Medicare Local

Address [1]

Now closed

Country [1]

Australia

Funding source category [2]

Government body

Name [2]

Better Care Victoria, Department of Health and Human Services

Address [2]

Department of Health and Human Services
50 Lonsdale Street Melbourne Victoria 3000

Country [2]

Australia

Primary sponsor type

Hospital

Name

Western Health, Sunshine Hospital

Address

176 Furlong Rd, St Albans, 3021, VIC

Country

Australia

Secondary sponsor category [1]

None

Name [1]

Address [1]

Country [1]

Ethics approval

Ethics application status

Approved

Ethics committee name [1]

Western Health Low Risk Ethics Panel

Ethics committee address [1]

Western Health Low Risk Ethics Panel
Office for Research, 176 Furlong Rd, St Albans, VIC 3021

Ethics committee country [1]

Australia

Date submitted for ethics approval [1]

04/07/2016

Approval date [1]

15/08/2016

Ethics approval number [1]

HREC/16/WH/124

Summary

Brief summary

Chronic diseases can be burdensome and are often interrelated. Chronic Kidney Disease (CKD), Cardiovascular Disease (CVD) and Type 2 Diabetes Mellitus (T2DM) are a cluster of interrelated chronic diseases sharing cardio-metabolic risk factors including obesity, hypertension and dyslipidaemia. Each are burdensome with around 10% of Australians (1.7 million) showing measured biomedical signs of CKD, an estimated 4.9% (just over 1 million) with diabetes and 22% of adult Australians (3.7 million) reporting that they had 1 or more CVD, including hypertensive disease, stroke, heart failure or heart disease. As many as 1 in 300 of the population have Familial Hypercholesterolemia (FH), the commonest autosomal dominant disorder in the community. Untreated FH can lead to death from coronary heart disease before age 60 while treated patients have a normal life expectancy. CKD, CVD and T2DM are in the top 10 for leading causes of death in Australia. They can have complex causal relationships between them leading to more severe illness and poorer prognosis. For example, CKD and T2DM are strong risk factors for future coronary events and all-cause mortality.
With CKD, CVD and T2DM requiring intensive management often over a long period of time the costs to the Australian community and health-care system is immense. They can lead to disability, loss of quality of life and premature death. In 2009, CKD accounted for approximately 2% of total health care expenditure, equivalent to ~ $900 million. In 2008-09 health care costs attributable to heart disease was $2.03 Billion. Diabetes directly costs the health care system approximately $1.7 billion per year, and indirectly, $14 billion per year. 
It is known that 85% of Australians visit a general practitioner (GP) each year. As such, efforts to increase awareness of chronic diseases and their risk factors amongst GPs as well as providing opportunities for improved screening and management in the general practice setting is essential in combating this growing public health concern.

Chronic Disease IMPACT (Chronic Disease early detection and Improved Management in PrimAry Care ProjecT) is an extension of the CKD-EMAP project and an initiative of Western Health, Victoria University the University of Melbourne. It is supported by a legacy grant from the former Macedon Ranges and North Western Melbourne Medicare Local. 

The Chronic Disease IMPACT project aims to further enhance primary care software to aid detection and management of chronic diseases focussing on CKD, CVD, Heart Failure, T2DM and risk factors such as Familial Hypercholesterolemia

Trial website

Trial related presentations / publications

Public notes

Contacts

Principal investigator

Name

A/Prof Craig Nelson

Address

Renal Services, Sunshine Hospital, 176 Furlong Rd, St Albans, 3021, VIC

Country

Australia

Phone

+61 3 8395 1348

Fax

craig.nelson@wh.org.au

Contact person for public queries

Name

Natalie Lumsden

Address

Renal Research Office, Sunshine Hospital, 176 Furlong Rd, St Albans, 3021, VIC

Country

Australia

Phone

+61 466 418 183

Fax

Natalie.Lumsden@wh.org.au

Contact person for scientific queries

Name

Craig Nelson

Address

Renal Services, Sunshine Hospital, 176 Furlong Rd, St Albans, 3021, VIC

Country

Australia

Phone

+61 3 8395 1348

Fax

craig.nelson@wh.org.au

Data sharing statement

Will individual participant data (IPD) for this trial be available (including data dictionaries)?

No/undecided IPD sharing reason/comment

n/a

What supporting documents are/will be available?

No Supporting Document Provided

Results publications and other study-related documents

Documents added manually

No documents have been uploaded by study researchers.

Documents added automatically

No additional documents have been identified.

Trial Review

Registering a new trial?

Documents added manually

Documents added automatically